AXNX News and Press, Axonics Modulation Technologies Inc. From 04/26/22

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will participate in the BofA Securities 2022 Healthcare Conference on May 10, 2022. Axonics is scheduled to pre...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the comprehensive launch of the Axonics F15 across the United States. The newly developed, long-liv...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report first quarter 2022 financial results after the market closes on Thursday, May 5, 2022. In conjuncti...

Axonics (NASDAQ:AXNX) launches its direct to consumer television advertising campaign "The Find Real Relief". The campaign is focused on women with any form of urinary incontinence, a large and significantly undertreated population and aims to reduce the stigma associated with these...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the launch of its direct to consumer television advertising campaign. The Find Real Relief ...

MedTech company Axonics (NASDAQ:AXNX) announced on Monday that the U.S. Food and Drug Administration (FDA) approved Axonics F15, its new recharge-free sacral neuromodulation (SNM) implantable neurostimulator (INS). Axonics F15 is designed to last for well over a decade inside the body without...

Axonics sets recharge-free neuromodulation benchmark with FDA labeling for 15+ years of functional life at typical stimulation parameters and 20+ years at lower energy settings Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and comme...

The following slide deck was published by Axonics, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Axonics, Inc. 2021 Q4 - Results - Earnings Call Presentation

Axonics, Inc. (AXNX) Q4 2021 Earnings Conference Call February 24, 2022, 4:30 PM ET Company Participants Raymond Cohen – Chief Executive Officer & Director Neil Bhalodkar – Vice President of Investor Relations Dan Dearen – President & Chief Financial Officer Confe...

Axonics Modulation Technologies press release (NASDAQ:AXNX): Q4 GAAP EPS of -$0.34 beats by $0.02. Revenue of $53.1M (+52.6% Y/Y) beats by $2.58M. For further details see: Axonics Modulation Technologies GAAP EPS of -$0.34 beats by $0.02, revenue of $53.1M beats by $2.58M